Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Ali Jabbari; Zhenpeng Dai; Luzhou Xing; Jane E Cerise; Yuval Ramot; Yackov Berkun; Gina A Montealegre Sanchez; Raphaela Goldbach-Mansky; Angela M Christiano; Raphael Clynes; Abraham Zlotogorski

doi:10.1016/j.ebiom.2015.02.015

Back

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Journal article

Open access

Peer reviewed

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

Ali Jabbari, Zhenpeng Dai, Luzhou Xing, Jane E Cerise, Yuval Ramot, Yackov Berkun, Gina A Montealegre Sanchez, Raphaela Goldbach-Mansky, Angela M Christiano, Raphael Clynes, …

EBioMedicine, Vol.2(4), pp.351-355

04/2015

DOI: 10.1016/j.ebiom.2015.02.015

PMCID: PMC4486197

PMID: 26137574

Files and links (1)

url

https://doi.org/10.1016/j.ebiom.2015.02.015View

Published (Version of record) Open Access

Abstract

Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules. A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib. The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment. Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.

Gene expression profiling

Autoinflammatory

CANDLE syndrome

JAK inhibitor

Autoimmune disease

Baricitinib

Alopecia areata

Interferon gamma

Details

Title: Subtitle: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Creators: Ali Jabbari - Department of Dermatology, Columbia University, New York, NY, USA
Zhenpeng Dai - Department of Dermatology, Columbia University, New York, NY, USA
Luzhou Xing - Department of Pathology, Columbia University, New York, NY, USA
Jane E Cerise - Department of Dermatology, Columbia University, New York, NY, USA
Yuval Ramot - Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Yackov Berkun - Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Gina A Montealegre Sanchez - Translational Autoinflammatory Disease Section, NIAMS, NIH, Bethesda, MD, USA
Raphaela Goldbach-Mansky - Translational Autoinflammatory Disease Section, NIAMS, NIH, Bethesda, MD, USA
Angela M Christiano - Department of Dermatology, Columbia University, New York, NY, USA
Raphael Clynes - Department of Dermatology, Columbia University, New York, NY, USA
Abraham Zlotogorski - Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Resource Type: Journal article
Publication Details: EBioMedicine, Vol.2(4), pp.351-355
DOI: 10.1016/j.ebiom.2015.02.015
PMID: 26137574
PMCID: PMC4486197
NLM abbreviation: EBioMedicine
ISSN: 2352-3964
eISSN: 2352-3964
Publisher: Elsevier B.V
Grant note: name: Locks of Love Foundation; name: Alopecia Areata Initiative; name: USPHS NIH/NIAMS, award: R01AR056016, R21AR061881; name: Shared Instrumentation Grant, award: S10RR027050; name: Columbia University Skin Disease Research Center, award: P30AR044535; name: NIAMS IRP; name: The Authority for Research and Development, Hebrew University of Jerusalem; name: Young Clinician's Grant; name: Hadassah-Hebrew University Medical Center
Language: English
Date published: 04/2015
Academic Unit: Dermatology
Record Identifier: 9984025339102771

Metrics

120 Record Views

176 Times Cited - Web of Science